Substance / Medication

Deferoxamine mesylate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage.
Yu Yao, Zhao Wei, Zhu Chunpeng et al. · PLoS One · 2015
PMID: 25875777RCTFull text (PMC)
Treatment of Hyperpigmentation After Sclerotherapy Through Mesotherapy With Deferoxamine Mesylate: A Case Series.
Mello Netto Brenno Augusto S, Zeilmann Eduardo, Santos Gilmar S et al. · Cureus · 2025
PMID: 41523378Case ReportFull text (PMC)
Rational synthesis of FeNiCo-LDH nanozyme for colorimetric detection of deferoxamine mesylate.
Qin Yuan, Li Shuishi, Liang Ling et al. · Spectrochim Acta A Mol Biomol Spectrosc · 2023
PMID: 37506456Other
Deferoxamine mesylate improves splicing and GAA activity of the common c.-32-13T>G allele in late-onset PD patient fibroblasts.
Buratti Emanuele, Peruzzo Paolo, Braga Luca et al. · Mol Ther Methods Clin Dev · 2021
PMID: 33426149OtherFull text (PMC)
Formulation and In-Vitro Characterization of Chitosan-Nanoparticles Loaded with the Iron Chelator Deferoxamine Mesylate (DFO).
Lazaridou Maria, Christodoulou Evi, Nerantzaki Maria et al. · Pharmaceutics · 2020
PMID: 32156022OtherFull text (PMC)
Deferoxamine Mesylate Improves the Survival Rate of Transplanted Fat by Promoting Angiogenesis.
Lin Yan, Zhang Xiaoyu, Li Haoran et al. · Aesthet Surg J · 2023
PMID: 36952294Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Deferoxamine mesilate (substance)
SNOMED CT
387224002
UMLS CUI
C0011148

Clinical Data

This intervention maps to 4 entities in the Healos knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.